Sumanta K Pal
City of Hope Medical Center · SWOG Cancer Research Network · City of Hope Comprehensive Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sumanta K Pal as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:34 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07578025 · Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on ImmunotherapyCity of Hope Medical Center · not yet recruiting · Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 · principal investigator
- Ph1NCT07128680 · Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerCity of Hope Medical Center · recruiting · Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma · principal investigator
- Ph1NCT06049576 · Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell CarcinomaCity of Hope Medical Center · suspended · Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 · principal investigator
- Ph1NCT05122546 · CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerCity of Hope Medical Center · active not recruiting · Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma, Advanced Renal Cell Carcinoma · principal investigator
- N/ANCT04961320 · Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell CarcinomaCity of Hope Medical Center · withdrawn · Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 · principal investigator
- N/ANCT04820894 · Perception of Cure Among Patients With Metastatic CancerCity of Hope Medical Center · withdrawn · Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm · principal investigator
- N/ANCT04812197 · Microbial Diversity Between Inflamed and Non-inflamed Skin of Patients With Immune Checkpoint Inhibitor-Induced DermatitisCity of Hope Medical Center · completed · Genito-Urinary Neoplasm · principal investigator
- N/ANCT04788095 · App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Cell CancerCity of Hope Medical Center · active not recruiting · Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 · principal investigator
- N/ANCT04688333 · iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With Localized Renal Cell CarcinomaCity of Hope Medical Center · withdrawn · Renal Cell Carcinoma · principal investigator
- Ph1NCT03829111 · CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney CancerCity of Hope Medical Center · completed · Advanced Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma · principal investigator
- Ph2NCT02761057 · Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has ProgressedNational Cancer Institute (NCI) · completed · Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7 · principal investigator
- Ph2NCT02567409 · Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial CancerNational Cancer Institute (NCI) · completed · Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Leadership, Planning and EvaluationP30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI JOHN D. CARPTEN · fiscal years 2011 to 2026
- SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026Named on NCT02761057
- NCI ETCTN Pittsburgh Cancer Consortium (PCC)UM1CA186690 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD, Farshid Dayyani, Liza Cosca Villaruz · fiscal years 2014 to 2026Named on NCT02567409
- Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTNUM1CA186717 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI A. Dimitrios Colevas, Alexey V. Danilov, PRIMO N. LARA, HEINZ JOSEF LENZ · fiscal years 2014 to 2026Named on NCT02567409
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:34 UTC. The ranking covers the 200 most relevant of 71 PubMed records, and a shared surname and initials can bring in a namesake. All 71 on PubMed
- 1,038 citationsRCR 31.3
- 447 citationsRCR 28.2
- Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.J Clin Oncol · 2017419 citationsRCR 11.9
- 415 citationsRCR 14.8
- 348 citationsRCR 12.8
- 245 citationsRCR 14.1
- 221 citationsRCR 12.9
- Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.Lancet Oncol · 2020212 citationsRCR 8.0
- 205 citationsRCR 15.9
- Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.J Clin Oncol · 2017158 citationsRCR 4.8